HSP

HSP90α-IN-1 is a selective inhibitor of HSP90α, with an IC50 value of 111 nM, demonstrating significant senolytic activity in diverse cellular senescence models. This compound is associated with the xanthinic family and plays a critical role in investigations aimed at addressing age-related inflammaging and associated diseases, including cancer. HSP90α-IN-1 is also being explored for its potential to promote healthy lifespan extension in various biological research contexts.

Pochonin D ((+)-Pochonin D) is a potent inhibitor of heat shock protein 90 (Hsp90) with demonstrated antiviral and anti-inflammatory activities. By targeting Hsp90, Pochonin D disrupts the proper folding, stabilization, and assembly of client proteins, including viral proteins, thereby impairing viral protein homeostasis and significantly reducing viral replication capacity. In addition, Pochonin D exhibits anti-inflammatory effects by attenuating inflammatory cell infiltration and suppressing the production of pro-inflammatory cytokines, such as TNF-α and IL-1β. These combined pharmacological properties highlight Pochonin D as a promising small-molecule tool for the study of human rhinovirus (HRV) infection and cancer-related pathways.

Hsp110-STAT3 PPI-IN-1 is a potent inhibitor of the Hsp110-STAT3 protein-protein interaction. This compound exhibits antiproliferative activity against the HPAEC cell line, demonstrating an IC50 value of 22.67 μM. It serves as a valuable tool for investigating the role of Hsp110-STAT3 interactions in various biological processes and therapeutic applications.

Aha1/Hsp90-IN-1 is a potent inhibitor of the Aha1/Hsp90 complex, demonstrating an IC50 value of 3.32 μM. By disrupting the interactions between Aha1 and Hsp90, this compound effectively inhibits tau aggregation. Research applications include studies of protein folding and aggregation diseases, making it a valuable tool in the exploration of neurodegenerative disorders.

Hsp90-IN-47 is a potent Hsp90 inhibitor, demonstrating an IC50 of 0.014 μM against Hsp90α. This compound exhibits significant antifungal properties, particularly when used in combination with Fluconazole, enhancing efficacy against fluconazole-resistant strains of Candida albicans. Additionally, Hsp90-IN-47 shows promising antitumor activity, particularly in acute myeloid leukemia and non-small cell lung cancer research applications.